{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:43:54Z","timestamp":1762868634166,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.neuint.2021.105209","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T20:03:03Z","timestamp":1634587383000},"page":"105209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects"],"prefix":"10.1016","volume":"151","author":[{"given":"Przemys\u0142aw J.","family":"Danek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Bromek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Haduch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W\u0142adys\u0142awa A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2009","series-title":"Drug Approval Package: Saphris NDA 22117 URL","key":"10.1016\/j.neuint.2021.105209_bib1"},{"key":"10.1016\/j.neuint.2021.105209_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2009.09.062","article-title":"The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: an in vitro study","volume":"626","author":"Bromek","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1471-4159.2011.07339.x","article-title":"Cytochrome P450 mediates dopamine formation in the brain in vivo","volume":"118","author":"Bromek","year":"2011","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2021.105209_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fpsyt.2018.00073","article-title":"Neurosteroids in schizophrenia: pathogenic and therapeutic implications","volume":"9","author":"Cai","year":"2018","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuint.2021.105209_bib5","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3109\/00498254.2013.791410","article-title":"Potential role of CYP2D6 in the central nervous system","volume":"43","author":"Cheng","year":"2013","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuint.2021.105209_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2014.908185","article-title":"Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism","volume":"10","author":"Citrome","year":"2014","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuint.2021.105209_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ph14070629","article-title":"The influence of long-term treatment with asenapine on liver cytochrome P450 expression and activity in the rat. The involvement of different mechanisms","volume":"14","author":"Danek","year":"2021","journal-title":"Pharmaceuticals (Basel)."},{"key":"10.1016\/j.neuint.2021.105209_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0278-5846(02)00317-2","article-title":"Mechanisms of cellular distribution of psychotropic drugs. Significance for drug action and interactions","volume":"27","author":"Daniel","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuint.2021.105209_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/17425255.1.2.203","article-title":"The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms","volume":"1","author":"Daniel","year":"2005","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuint.2021.105209_bib10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1211\/002235702162","article-title":"Inhibition and possible induction of rat CYP2D after short- and long-term treatment with antidepressants","volume":"54","author":"Daniel","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib11","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1124\/mol.112.078709","article-title":"D\u2082-dopaminergic receptor-linked pathways: critical regulators of CYP3A, CYP2C, and CYP2D","volume":"82","author":"Daskalopoulos","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neuro.2018.03.009","article-title":"Aminochrome decreases NGF, GDNF and induces neuroinflammation in organotypic midbrain slice cultures","volume":"66","author":"de Ara\u00fajo","year":"2018","journal-title":"Neurotoxicology"},{"year":"2010","series-title":"Sycrest International Nonproprietary Name: Asenapine Procedure No","key":"10.1016\/j.neuint.2021.105209_bib13"},{"key":"10.1016\/j.neuint.2021.105209_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-007-0973-y","article-title":"Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia","volume":"196","author":"Fr\u00e5nberg","year":"2008","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuint.2021.105209_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2133\/dmpk.18.337","article-title":"CYP2D in the brain","volume":"18","author":"Funae","year":"2003","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.neuint.2021.105209_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.drudis.2016.06.004","article-title":"Pathophysiological implications of neurovascular P450 in brain disorders","volume":"21","author":"Ghosh","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuint.2021.105209_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.vph.2014.01.008","article-title":"Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation","volume":"60","author":"Grossini","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib18","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/03602532.2018.1554674","article-title":"The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders","volume":"50","author":"Haduch","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neuint.2021.105209_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejphar.2010.10.077","article-title":"The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain","volume":"651","author":"Haduch","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib20","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S1734-1140(13)71513-5","article-title":"Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters","volume":"65","author":"Haduch","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuint.2021.105209_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.phrs.2012.10.009","article-title":"The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study","volume":"67","author":"Haduch","year":"2013","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuint.2021.105209_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/jnc.13031","article-title":"The cytochrome P450 2D-mediated formation of serotonin from 5-methoxytryptamine in the brain in vivo: a microdialysis study","volume":"133","author":"Haduch","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuint.2021.105209_bib23","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bcp.2018.09.005","article-title":"The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat","volume":"156","author":"Haduch","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2020.104884","article-title":"The effect of ageing and cerebral serotonin deficit on the activity of cytochrome P450 2D (CYP2D) in the brain and liver of male rats","volume":"141","author":"Haduch","year":"2020","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.neuint.2021.105209_bib25","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0026-895X(25)09238-7","article-title":"Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene","volume":"50","author":"Hedlund","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2174\/1389200013338513","article-title":"Cytochrome P450 in the brain; a review","volume":"2","author":"Hedlund","year":"2001","journal-title":"Curr. Drug Metabol."},{"key":"10.1016\/j.neuint.2021.105209_bib27","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","article-title":"Dopamine formation from tyramine by CYP2D6","volume":"249","author":"Hiroi","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neuint.2021.105209_bib28","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1210\/endo.142.9.8363","article-title":"Progesterone oxidation by cytochrome P450 2D isoforms in the brain","volume":"142","author":"Hiroi","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuint.2021.105209_bib29","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1124\/dmd.30.9.970","article-title":"Catalytic specificity of CYP2D isoforms in rat and human","volume":"30","author":"Hiroi","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuint.2021.105209_bib30","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1210\/en.2003-1109","article-title":"Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain","volume":"145","author":"Kishimoto","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuint.2021.105209_bib31","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1016\/0006-2952(89)90433-4","article-title":"The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man","volume":"38","author":"Kobayashi","year":"1989","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0006-2952(01)00843-7","article-title":"Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat","volume":"63","author":"Kobayashi","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03602532.2020.1858856","article-title":"Cytochrome P450 expression and regulation in the brain","volume":"53","author":"Kuban","year":"2021","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neuint.2021.105209_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.neuint.2021.105209_bib35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S1092852912000752","article-title":"New insights into the mechanism of drug-induced dyskinesia","volume":"18","author":"Loonen","year":"2013","journal-title":"CNS Spectr."},{"key":"10.1016\/j.neuint.2021.105209_bib36","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuint.2021.105209_bib37","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","article-title":"Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment","volume":"55","author":"Mann","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuint.2021.105209_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","article-title":"Asenapine effects in animal models of psychosis and cognitive function","volume":"206","author":"Marston","year":"2009","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuint.2021.105209_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.schres.2019.12.031","article-title":"Systematic review and meta-analysis of the relationship between genetic risk for schizophrenia and facial emotion recognition","volume":"218","author":"Martin","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.neuint.2021.105209_bib40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/BF03033368","article-title":"Antipsychotic-induced oxidative stress in rat brain","volume":"13","author":"Martins","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuint.2021.105209_bib41","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pharmthera.2017.10.008","article-title":"CYP-mediated drug metabolism in the brain impacts drug response","volume":"184","author":"McMillan","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuint.2021.105209_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1503\/jpn.120133","article-title":"Cytochrome P450-mediated drug metabolism in the brain","volume":"38","author":"Miksys","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.neuint.2021.105209_bib43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/004982500406390","article-title":"Regional and cellular distribution of CYP2D subfamily members in rat brain","volume":"30","author":"Miksys","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1016\/j.neuint.2021.105209_bib44","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/157015909790031229","article-title":"Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib45","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/bph.12652","article-title":"Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys","volume":"171","author":"Miller","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib46","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/0006-2952(94)90069-8","article-title":"Differential roles of cytochromes P450 2D1, 2C11, and 1A1\/2 in the hydroxylation of bufuralol by rat liver microsomes","volume":"47","author":"Mimura","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib47","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/mp.2012.47","article-title":"Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents","volume":"17","author":"Miyamoto","year":"2012","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuint.2021.105209_bib48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.neures.2011.01.004","article-title":"Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells","volume":"69","author":"Park","year":"2011","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuint.2021.105209_bib49","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"P T"},{"year":"2007","series-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","key":"10.1016\/j.neuint.2021.105209_bib50"},{"key":"10.1016\/j.neuint.2021.105209_bib51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40263-016-0363-2","article-title":"Asenapine: a review in schizophrenia","volume":"30","author":"Plosker","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuint.2021.105209_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3389\/fendo.2019.00169","article-title":"Neurosteroid actions in memory and neurologic\/neuropsychiatric disorders","volume":"10","author":"Ratner","year":"2019","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.neuint.2021.105209_bib53","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcp.2016.04.017","article-title":"The reverse role of the hypothalamic paraventricular (PVN) and arcuate (ARC) nuclei in the central serotonergic regulation of the liver cytochrome P450 isoform CYP2C11","volume":"112","author":"Rysz","year":"2016","journal-title":"Biochem. Pharmacol."},{"year":"2013","series-title":"Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","key":"10.1016\/j.neuint.2021.105209_bib54"},{"key":"10.1016\/j.neuint.2021.105209_bib55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/clpt.1988.76","article-title":"Inhibition of desipramine 2-hydroxylation by quinidine and quinine","volume":"43","author":"Steiner","year":"1988","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuint.2021.105209_bib56","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00213-021-05808-9","article-title":"The role of CYP2D in rat brain in methamphetamine-induced striatal dopamine and serotonin release and behavioral sensitization","volume":"287","author":"Stocco","year":"2021","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.neuint.2021.105209_bib57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1358\/dot.2009.45.12.1421561","article-title":"Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania","volume":"45","author":"Tarazi","year":"2009","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.neuint.2021.105209_bib58","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/syn.20618","article-title":"Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain","volume":"63","author":"Tarazi","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neuint.2021.105209_bib59","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-3565(24)39180-3","article-title":"Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid","volume":"294","author":"Thompson","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuint.2021.105209_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/03602532.2016.1221960","article-title":"Emerging roles for brain drug-metabolizing cytochrome P450 enzymes in neuropsychiatric conditions and responses to drugs","volume":"48","author":"Toselli","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.neuint.2021.105209_bib61","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1124\/dmd.110.036715","article-title":"Metabolism and excretion of asenapine in healthy male subjects","volume":"39","author":"van de Wetering-Krebbers","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.neuint.2021.105209_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0706743718773728","article-title":"An overview of animal models related to schizophrenia","volume":"64","author":"Winship","year":"2019","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.neuint.2021.105209_bib63","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s43440-020-00089-z","article-title":"In vitro inhibition of human cytochrome P450 enzymes by the novel atypical antipsychotic drug asenapine: a prediction of possible drug-drug interactions","volume":"72","author":"W\u00f3jcikowski","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuint.2021.105209_bib64","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0026-895X(25)09739-1","article-title":"Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes","volume":"46","author":"Yamazaki","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuint.2021.105209_bib65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1139\/jpn.0808","article-title":"Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course","volume":"33","author":"Yue","year":"2008","journal-title":"J. Psychiatry Neurosci."}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018621002552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018621002552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:55:20Z","timestamp":1759312520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018621002552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":65,"alternative-id":["S0197018621002552"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2021.105209","relation":{},"ISSN":["0197-0186"],"issn-type":[{"type":"print","value":"0197-0186"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic treatment with asenapine affects cytochrome P450 2D (CYP2D) in rat brain and liver. Pharmacological aspects","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2021.105209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105209"}}